FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio BY Vandana Singh • July 16, 2026July 17, 2026 On Thursday, the U.S. Food and Drug Administration (FDA) approved Merck & Co Inc.’s (NYSE:MRK) LIPFENDRA (enlicitide) as an adjunct to reduce low-density lipoprotein cholesterol (LDL-C) in adults[...] Read more
